Do you remember what you were wearing on 1 December 2019? Probably not. I do though. I was wearing a blue Valencia Marathon t-shirt, an exhausted but elated perma-grin and
Clinical trials are essential for testing new treatments for metastatic breast cancer. For patients, they represent hope – the chance to get access to a new potential treatment before it
Tassia Haines – METUPUK (Wales) member, patient advocate & fantastic artist. Back in February, I had to go into hospital after side effects from being on Trodelvy. I wanted
The human brain is hardwired to seek out danger. It’s part of being human, an inbuilt survival mechanism designed to protect us. Normal functioning of the mind enables us to
Scientific research is vital for the development of new and improved treatments for secondary breast cancer. But what’s it like to be a scientist working in this area? Dr Hannah Harrison received her PhD in breast cancer research from the University of Manchester in 2009 and has since worked as a breast cancer research scientist in the Manchester Cancer Research Centre. Here, Hannah tells us about her work.
At METUPUK, we campaign for new and better therapies for patients with secondary breast cancer. One of our recent campaigns, #TrodelvyNow helped to make a new type of drug, Trodelvy (sacituzumab govitecan) available for SBC patients in the UK. Scientist and METUPUK volunteer, Helen, explains how Trodelvy works and why it’s important that more drugs like this get to patients urgently.
METUPUK are delighted by the Scottish Medicines Consortium (SMC) acceptance of Enhertu (trastuzumab deruxtecan) for routine use on the NHS. The Scottish Medicines Consortium (SMC) has accepted: Trastuzumab deruxtecan (Enhertu)
METUPUK are devastated by the news that one of our Trustees and friend Connie Johncock has died. Connie was a founder trustee of METUPUK and our Treasurer, overseeing our finances as we
The Scottish Medicines Consortium (SMC) have decided against funding the metastatic breast cancer drug alpelisib (Piqray).
METUPUK welcomes the Scottish Medicines Consortium (SMC) decision to accept pembrolizumab (Keytruda, Merck Sharp and Dohme) plus chemotherapy (paclitaxel or nab-paclitaxel) for use on the NHS in Scotland. Pembrolizumab is